Car-T clinical trials
Car-T is named as an intervention in 17 current clinical trials in our China, Germany and Netherlands registers. 12 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (3). The most-studied condition is B-cell Acute Lymphoblastic Leukemia.
Patient leaflets for Car-T
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Car-T
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Car-T
22 conditionsAll 22 conditions
| Condition (as registered) | Trials |
|---|---|
| B-cell Acute Lymphoblastic Leukemia | 2 |
| Multiple Myeloma | 2 |
| Relapsed/Refractory Multiple Myeloma | 2 |
| Plasma Cell Leukemia | 2 |
| Mantle Cell Lymphoma | 1 |
| Relapsed B-cell Acute Lymphoblastic Leukemia | 1 |
| Refractory B-cell Acute Lymphoblastic Leukemia | 1 |
| B ALL | 1 |
| Allogenetic Hematopoietic Stem Cell Transplantation | 1 |
| MRD-positive | 1 |
| B-NHL | 1 |
| CART Therapy | 1 |
| Relapsed or Refractory Aggressive B-cell Lymphoma | 1 |
| B-cell Lymphoma | 1 |
| Hematological Malignancy | 1 |
| Multiple Myeloma, Newly Diagnosed | 1 |
| AML (Acute Myeloid Leukemia) | 1 |
| T-lymphoblastic Lymphoma | 1 |
| T-ALL | 1 |
| B-cell Non Hodgkin Lymphoma | 1 |
| Large B-Cell Lymphoma | 1 |
| CD7 Positive R/R PTCL | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 16 | 11 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Car-T trials
How many clinical trials are testing Car-T?
17 current trials in our China, Germany and Netherlands registers name Car-T (also registered as CAR-GPRC5D) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Car-T trials recruiting patients?
Yes. 12 of the 17 trials are recruiting: 11 with sites in China, 1 with sites in Germany and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Car-T clinical trials?
Institute of Hematology & Blood Diseases Hospital, China (3), Peking University People's Hospital (2), Ruijin Hospital (2) and Xuzhou Medical University (2), among 12 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Car-T works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Car-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Car-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.